SET2,3预测II-III期HR+/HER2-乳腺癌化疗内分泌治疗前内分泌治疗敏感性
本研究提出SET2,3检测(SETER/PR指数联合基线预后指数BPI)用于评估II-III期HR+/HER2-乳腺癌患者内分泌治疗敏感性。在MDACC队列(n=307)和I-SPY2试验(n=268)中,SET2,3对远处无复发生存提供独立于RCB的预后信息(MDACC HR 0.23,P=0.004;I-SPY2 HR 0.27,P=0.031)。约40%临床高危HR+/HER2-患者具有高SET2,3,可考虑新辅助内分泌治疗临床试验。
要点
- SET2,3可独立于RCB预测HR+/HER2-乳腺癌远处复发风险。
- 其他分子预后特征不能替代SETER/PR指数,但可替代RNA4亚型。
- 约40%临床高危患者SET2,3高,或可考虑新辅助内分泌治疗试验。
核心结论
- SET2,3在化疗反应(RCB)和基线预后评分或亚型之外提供独立预后信息。
研究设计与样本
- 在MDACC队列(n=307,随访11年,U133A芯片)中评估SET2,3并确定切点,随后在I-SPY2试验(n=268,高危MammaPrint结果,随访3.8年,Agilent-44K芯片)中独立盲法验证。
主要发现
- MDACC队列中SET2,3(HR 0.23,P=0.004)和RCB(HR 1.77,P<0.001)与远处无复发生存独立相关。
- I-SPY2试验中SET2,3(HR 0.27,P=0.031)和RCB(HR 1.68,P=0.008)与远处无复发生存独立相关。
- 无论RCB-II或RCB-III,以及两种luminal亚型,SET2,3提供相似预后信息;RCB在SET2,3低的癌症中预后最强(MDACC P<0.001,I-SPY2 P<0.001)。
- 其他分子特征无独立预后价值,可有效替代SET2,3中BPI组分的RNA4亚型,但不能有效替代SETER/PR指数。
关键数值与推荐
- SET2,3检测基于治疗前肿瘤活检,测量SETER/PR指数并依据临床肿瘤和淋巴结分期及RNA4(ESR1、PGR、ERBB2、AURKA)分子亚型调整的基线预后指数(BPI)。
- 主要终点为远处无复发生存。
临床怎么用
- 对于临床高危HR+/HER2-乳腺癌患者,SET2,3可辅助评估内分泌治疗敏感性,指导治疗决策。
- SET2,3高的患者(约40%)可考虑参加新辅助内分泌治疗临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We proposed that a test for sensitivity to the adjuvant endocrine therapy component of treatment for patients with stage II-III breast cancer (SET2,3) should measure transcription related to estrogen and progesterone receptors (SETER/PR index) adjusted for a baseline prognostic index (BPI) combining clinical tumor and nodal stage with molecular subtype by RNA4 (ESR1, PGR, ERBB2, and AURKA). PATIENTS AND METHODS: Patients with clinically high-risk, hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2-) breast cancer received neoadjuvant taxane-anthracycline chemotherapy, surgery with measurement of residual cancer burden (RCB), and then adjuvant endocrine therapy. SET2,3 was measured from pre-treatment tumor biopsies, evaluated first in an MD Anderson Cancer Center (MDACC) cohort (n = 307, 11 years' follow-up, U133A microarrays), cut point was determined, and then independent, blinded evaluation was carried out in the I-SPY2 trial (n = 268, high-risk MammaPrint result, 3.8 years' follow-up, Agilent-44K microarrays, NCI Clinical Trials ID: NCT01042379). Primary outcome measure was distant relapse-free survival. Multivariate Cox regression models tested prognostic independence of SET2,3 relative to RCB and other molecular prognostic signatures, and whether other prognostic signatures could substitute for SETER/PR or RNA4 components of SET2,3. RESULTS: SET2,3 added independent prognostic information to RCB in the MDACC cohort: SET2,3 [hazard ratio (HR) 0.23, P = 0.004] and RCB (HR 1.77, P < 0.001); and the I-SPY2 trial: SET2,3 (HR 0.27, P = 0.031) and RCB (HR 1.68, P = 0.008). SET2,3 provided similar prognostic information irrespective of whether RCB-II or RCB-III after chemotherapy, and in both luminal subtypes. Conversely, RCB was most strongly prognostic in cancers with low SET2,3 status (MDACC P < 0.001, I-SPY2 P < 0.001). Other molecular signatures were not independently prognostic; they could effectively substitute for RNA4 subtype within the BPI component of SET2,3, but they could not effectively substitute for SETER/PR index. CONCLUSIONS: SET2,3 added independent prognostic information to chemotherapy response (RCB) and baseline prognostic score or subtype. Approximately 40% of patients with clinically high-risk HR+/HER2- disease had high SET2,3 and could be considered for clinical trials of neoadjuvant endocrine-based treatment.
引用
- Du L, Yau C, Brown-Swigart L, et al. Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy. Ann Oncol. 2021. PMID: 33617937. doi:10.1016/j.annonc.2021.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。